Relevance of Maintenance Therapy Using Lenalidomide (Revimid®) After Autologous Stem Cell Transplantation Patients Under the Age Of 65. (Open, Randomised, Multi-centric Trial Versus Placebo).
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Determine the efficacy of Revlimid® at prolonging the duration of the post-transplant response.
2 years
Yes
ATTAL Michel, Pr
Principal Investigator
University Hospital, Toulouse
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
0400401
NCT00430365
June 2006
June 2015
Name | Location |
---|